1. [Treatment of ocular cicatricial pemphigoid with sulfasalazine]
- Author
-
M. Savoldelli, Serge Doan, Jean-Francois Lerouic, Hervé Robin, Catherine Prost, and Thanh Hoang-Xuan
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Eye Diseases ,Eye disease ,medicine.medical_treatment ,Pemphigoid, Benign Mucous Membrane ,Administration, Oral ,Dapsone ,Autoimmune Diseases ,Drug withdrawal ,Oral administration ,Sulfasalazine ,Pemphigoid, Bullous ,medicine ,Humans ,Adverse effect ,Retrospective Studies ,Aged ,Aged, 80 and over ,Chemotherapy ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Retrospective cohort study ,medicine.disease ,Conjunctivitis ,Dermatology ,Blood Cell Count ,Ophthalmology ,Treatment Outcome ,Chronic Disease ,Drug Evaluation ,Female ,business ,Follow-Up Studies ,medicine.drug - Abstract
Purpose To assess the outcome of patients with ocular cicatricial pemphigoid (OCP) treated with sulfasalazine as an alternative to dapsone. Design Retrospective noncomparative case series. Participants Nine patients with biopsy-proven OCP and previous dapsone-related adverse effects (hemolysis and gastrointestinal disturbances) treated with oral sulfasalazine. Methods Clinical data were abstracted from patients' medical records. Main outcome measures Patients' symptoms, ocular inflammation, conjunctival scarring, complete blood cell count (including reticulocyte count). Results At the initiation of sulfasalazine therapy, ocular inflammation was controlled in all patients but one. Mean follow-up was 12 months (range, 2–35 months). Median oral sulfasalazine dosage was 3 g (range, 1–4 g). The disease remained controlled with sulfasalazine alone in four patients (45%). Two patients (22%) required adjunctive oral cyclophosphamide. Adverse effects necessitating drug withdrawal occurred in three patients (33%): hemolysis in two and gastrointestinal disturbances in one. Conclusions Sulfasalazine may be useful in OCP patients with previous dapsone-related adverse effects.
- Published
- 1999